Dr Mohammad (Mo) Haskali graduated with a Ph.D. in Radiopharmaceutical Sciences from the University of Melbourne. In 2013, he joined Cyclotek Pty. Ltd., where he worked until 2014. He then furthered his academic and clinical expertise in radiopharmaceutical development at the National Institute of Mental Health (NIMH) in the USA from 2014 to 2016. Following this, Dr Haskali joined the Peter MacCallum Cancer Centre (PMCC), serving as a Senior Radiopharmaceutical Scientist from 2016 to 2023. He currently holds the position of PMCC’s inaugural Chief Radiopharmaceutical Scientist. In this role, Dr Haskali leads the clinical provision of radiopharmaceuticals, which are drugs capable of detecting and targeting tumours for destruction. He also spearheads a research program focused on developing new radioactive drugs for clinical use. Dr Haskali has a strong personal interest in the chemical aspects of discovering, developing, and evaluating novel radioactive probes for molecular imaging with PET and targeted radionuclide therapy. Dr Haskali is a certified Radiopharmaceutical Scientist by the Australasian College of Physical Scientists and Engineers in Medicine (ACPSEM). Since 2019, he has served on the Professional Standards Board (PSB) of ACPSEM as the national representative of Radiopharmaceutical Sciences in Australia.